Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.93 EUR | +2.12% |
|
-9.13% | +10.53% |
06-14 | Hansoh Pharmaceutical Slashes Conversion Price of Convertible Bonds | MT |
04-29 | Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- With a 2024 P/E ratio at 25.84 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.53% | 12.17B | - | ||
+55.19% | 801B | C+ | ||
+47.26% | 631B | B | ||
-6.09% | 359B | C+ | ||
+21.92% | 337B | B- | ||
+18.40% | 245B | B+ | ||
+3.64% | 231B | A+ | ||
+12.98% | 219B | B- | ||
+10.86% | 171B | C+ | ||
-2.78% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 3692 Stock
- 3KY Stock
- Ratings Hansoh Pharmaceutical Group Company Limited